1-3 of 3
Riadh Lobbardi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CFT8634, a Clinical Stage BRD9 Bi DAC™ Degrader, Is Active in a Subset of Multiple Myeloma Cell Line Models and Synergistic When Combined with Pomalidomide

Laura L Poling, David Cocozziello, Minsheng He, Eunju Hurh, Riadh Lobbardi, Katrina L Jackson, Stewart L Fisher, Roy M Pollock
Journal: Blood
Blood (2023) 142 (Supplement 1): 6594.
https://doi.org/10.1182/blood-2023-174555
Published: 2023
Journal Articles

CFT7455, a Novel IKZF1/3 Degrader, Demonstrates Potent Anti-Tumor Activity in Models of Non-Hodgkin's Lymphoma As a Single Agent or in Combination with Clinically Approved Agents

Samantha Perino, R. Jason Kirby, Roman Agafonov, Prasoon Chaturvedi, Scott Eron, Andrew Good, Ashley Hart, Minsheng He, Riadh Lobbardi, Andrew J Phillips, David Proia, James Henderson, Michael Thomeius, Christopher Nasveschuk, Stewart L Fisher, Roy Macfarlane Pollock
Journal: Blood
Blood (2022) 140 (Supplement 1): 11575.
https://doi.org/10.1182/blood-2022-166541
Published: 2022
Journal Articles

Thymocyte Selection-Associated High-Mobility Group Box Protein (TOX) Induces Genomic Instability in T-Cell Acute Lymphoblastic Leukemia

Riadh Lobbardi, PhD, Jordan Pinder, PhD, Barbara Martinez-Pastor, PhD, Jessica S Blackburn, PhD, Nouran Abdelfattah, Deborah Toiber, PhD, Manon De Waard, John M. Asara, PhD, Raul Mostoslavsky, MDPhD, Graham Dellaire, PhD, David M. Langenau, PhD
Journal: Blood
Blood (2014) 124 (21): 475.
https://doi.org/10.1182/blood.V124.21.475.475
Published: 2014